Selecta Biosciences, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2008-01-01
- Employees
- 64
- Market Cap
- -
- Website
- http://www.selectabio.com
Clinical Trials
7
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
A Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SEL-302 in Pediatric Subjects With MMA
- First Posted Date
- 2023-03-21
- Last Posted Date
- 2023-05-08
- Lead Sponsor
- Selecta Biosciences, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT05778877
- Locations
- 🇺🇸
National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, United States
A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Participants Refractory to Conventional Therapy
- First Posted Date
- 2019-04-05
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Selecta Biosciences, Inc.
- Target Recruit Count
- 170
- Registration Number
- NCT03905512
- Locations
- 🇺🇸
Pinnacle Research Group, LLC, Anniston, Alabama, United States
🇺🇸Arizona Arthritis & Rheumatology Research, PLLC, Sun City, Arizona, United States
🇺🇸Baptist Health Center for Clinical Research, Little Rock, Arkansas, United States
Safety and Pharmacodynamcis of SELA-070 Nicotine Vaccine in Smokers
- Conditions
- Smoking Cessation
- First Posted Date
- 2017-05-11
- Last Posted Date
- 2018-11-16
- Lead Sponsor
- Selecta Biosciences, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT03148925
- Locations
- 🇧🇪
SGS LSS Clinical Pharmacology Unit, Antwerpen, Belgium
Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid
- Conditions
- Gout ChronicHyperuricemia
- Interventions
- First Posted Date
- 2016-11-09
- Last Posted Date
- 2022-02-14
- Lead Sponsor
- Selecta Biosciences, Inc.
- Target Recruit Count
- 152
- Registration Number
- NCT02959918
- Locations
- 🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States
🇺🇸Tri West Research Associates LLC, El Cajon, California, United States
🇺🇸Irvine Center for Clinical Research Inc., Irvine, California, United States
Safety and Pharmacodynamics of SEL-212 (Pegsiticase + SEL-110) in Subjects With Elevated Blood Uric Acid Levels
- First Posted Date
- 2016-01-07
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- Selecta Biosciences, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT02648269
- Locations
- 🇺🇸
Baptist Health Center for Clinical Research, Little Rock, Arkansas, United States
🇺🇸Miami Research Associates, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Inc., Orlando, Florida, United States
- Prev
- 1
- 2
- Next
News
Hyperuricemia Pipeline Shows Promise with 15+ Emerging Therapies in Development
Global hyperuricemia pipeline comprises 12+ key companies developing 15+ treatment therapies across various clinical stages, according to DelveInsight's 2025 report.